title: Metabolic support during coronary reperfusion.
abstract: The limitation of infarct size by thrombolysis could potentially be improved by an early metabolic intervention. We therefore evaluated the effects of a 48-hour infusion of glucose-insulin-potassium (GIK) in patients with anterior infarctions. Seventeen patients were randomized to receive intravenous GIK (n = 10) or placebo (n = 7). All patients additionally received streptokinase. Changes in left ventricular function were assessed by comparing the global ejection fractions and the regional infarct area ejection fractions of the first ventriculogram with the 10-day second ventriculogram. There was a significantly greater improvement in the global ejection fraction of patients receiving GIK (increases 0.07 +/- 0.04) than in those randomized to placebo (decreases 0.08 +/- 0.04) (p less than 0.02). There was also a much greater improvement in the area ejection fractions of the group receiving GIK vs the group receiving placebo in the anterolateral (increases 0.24 +/- 0.07 vs decreases 0.02 +/- 0.04 [p less than 0.02]) and diaphragmatic (increases 0.08 +/- 0.08 vs decreases 0.17 +/- 0.05 [p less than 0.005]) segments. Thus in patients with anterior infarctions receiving streptokinase, GIK improves ventricular function and reduces the size of the segmental wall motion abnormality.
authors.forename: L F
authors.initials: LF
authors.lastname: Satler
authors.forename: C E
authors.initials: CE
authors.lastname: Green
authors.forename: K M
authors.initials: KM
authors.lastname: Kent
authors.forename: R S
authors.initials: RS
authors.lastname: Pallas
authors.forename: D L
authors.initials: DL
authors.lastname: Pearle
authors.forename: C E
authors.initials: CE
authors.lastname: Rackley
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003326:Coronary Circulation; D003328:Coronary Thrombosis / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D005947:Glucose / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010477:Perfusion / Q000379:methods*; D011188:Potassium / Q000008:administration & dosage*; D011897:Random Allocation; D013300:Streptokinase / Q000627:therapeutic use; D013318:Stroke Volume
chemical_list: D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D013300:Streptokinase; D005947:Glucose; D011188:Potassium